Skip to content

Energy Specific Far Infrared Radiation Treatment for AIDS

Phase 1 Study to Evaluate the Efficacy of Using Energy Specific Far Infrared Radiation Treatment for HIV/AIDS

Status
UNKNOWN
Phases
Phase 1
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT00574522
Enrollment
3
Registered
2007-12-17
Start date
2008-02-29
Completion date
2009-11-30
Last updated
2009-08-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

HIV Infections

Keywords

HIV, AIDS, Radiation, Far infrared, Treatment, Acquired Immunodeficiency Syndrome, Complimentary therapies

Brief summary

The investigators are proposing that energy specific electromagnetic radiation of the central nervous system, the viscera and the endocrine system has the potential to enhance the immune system; thereby enhancing the production of killer cells to fight and destroy the human immunodeficiency virus.

Detailed description

Acquired immune deficiency syndrome or acquired immunodeficiency syndrome (AIDS or Aids) is a collection of symptoms and infections resulting from the specific damage to the immune system caused by the human immunodeficiency virus (HIV) in humans. The late stage of the condition leaves individuals prone to opportunistic infections and tumors. Although treatments for AIDS and HIV exist to slow the virus' progression, there is no known cure. The investigators are postulating that energy specific electromagnetic radiation of the central nervous system, the viscera and the endocrine system has the potential to enhance the immune system; thereby enhancing the production of CD4+ T cells and other killer cells to fight and destroy the human immunodeficiency virus. The primary end point is to determine the therapeutic effects of far infrared radiation (5μm to 20μm wavelength) on HIV/AIDS.

Interventions

RADIATIONFar infrared

Far infrared radiation with the wavelength between 5μm and 20μm for 30 to 40 minutes per session.

Sponsors

GAAD Medical Research Institute Inc.
Lead SponsorOTHER

Study design

Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE

Eligibility

Sex/Gender
ALL
Healthy volunteers
No

Inclusion criteria

* 1 Year and above

Exclusion criteria

* None

Design outcomes

Primary

MeasureTime frame
The primary end point is to determine the therapeutic effects of far infrared radiation (5μm to 15μm wavelength) on HIV/AIDS.One year

Countries

Canada

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026